The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Total excreted radioactivity (Ae)
Timeframe: Through 168 hours postdose
Cumulative recovery of total excreted radioactivity (CUM Ae)
Timeframe: Through 168 hours postdose
Area under the concentration-time curve (AUC) for RE104 and 4-OH-DiPT
Timeframe: Through 168 hours postdose
Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT
Timeframe: Through 168 hours postdose
Time to reach Cmax (Tmax) for RE104 and 4-OH-DiPT
Timeframe: Through 168 hours postdose
Terminal half-life (t1/2) of RE104 and 4-OH-DiPT
Timeframe: Through 168 hours postdose
Apparent terminal elimination half-life (λz) for RE104 and 4-OH-DiPT
Timeframe: Through 168 hours postdose
Mean residence time (MRT)
Timeframe: Through 168 hours postdose
Apparent total body clearance (CL/F) for RE104
Timeframe: Through 168 hours postdose
Apparent volume of distribution during the terminal phase (Vz/F) for RE104
Timeframe: Through 168 hours postdose
Total metabolite profiling with description of relevant PK parameters and structural identification of major metabolites present in all matrices
Timeframe: Through 168 hours postdose